Company: NCEL
Filing Date: 2025-03-10
Form Type: 425
Source: 0001213900-25-021979
Chunk: 2

Company: NewcelX Ltd.
Filing Date: 2025-03-10
Form: 425
Chunk 2
---
 of
Inversago Pharma for up to $1.075 billion highlights the strategic emphasis on developing novel therapies for obesity, diabetes, and
related metabolic disorders. Similarly, Roche’s $2.7 billion acquisition of Carmot Therapeutics reflects their concerted
effort to expand into the diabetes and obesity markets. Additionally, Sana Biotechnology has made significant advancements in the
diabetes space, with early clinical data suggesting their hypo immune platform could enable insulin production without
immunosuppression, positioning them as a potential leader in developing transformative treatments for type 1 diabetes. We believe
that these developments underscore the sector’s robust growth and the immense potential it holds for innovative
treatments.

Furthermore, we are expanding our diabetes treatment
strategies beyond GLP-1 therapies. By integrating complementary approaches, we aim to address the multifaceted challenges of diabetes
management, including neuroinflammation and metabolic resilience.

Advancements in Neurodegenerative Disease Treatment

Post-merger, we plan to prepare and initiate a
Phase IIa multi-site clinical trial of AstroRx®, Kadimastem’s product candidate for Amyotrophic Lateral Sclerosis (ALS). This
trial is slated to commence following the merger’s completion, marking significant progress in our neurodegenerative disease treatment
pipeline.

Experienced International Leadership Team

We believe that Kadimastem contributes to the
merger with its experienced international leadership team and board of directors, and with the teams prior experience developing medicine
from the laboratory to the market. For example, Rebif®, a blockbuster drug invented by Professor Michel Revel, Chief Scientist at
Kadimastem, in his capacity as a scientific investigator at the world-renowned Weizmann Institute of Science, was acquired by Merck Serono.
In addition, Ronen Twito, Kadimastem’s Executive Chairman and Chief Executive Officer, brings extensive experience working in the
U.S. capital market and M&A international market.

Advancements in DOXA R&D Programs

Our promising Dual Orexin Receptor Agonist (“DOXA”)
platform has made significant strides. The development of AEX-41 and AEX-2 compounds showcases our dedication to addressing unmet needs
in sleep-wake disorders. Preliminary studies have yielded promising results, reinforcing our confidence in these compounds’ potential
to transform patient care.

Additional Pipeline Expansion and Research Initiatives

Our commitment to addressing critical health challenges
remains steadfast:

| ● | Fentanyl Dependence Treatment: